RT Journal Article SR Electronic T1 Population homogeneity for the antibody response to COVID-19 Comirnaty vaccine is only reached after the second dose JF medRxiv FD Cold Spring Harbor Laboratory Press SP 2021.03.19.21253680 DO 10.1101/2021.03.19.21253680 A1 João F. Viana A1 Marie-Louise Bergman A1 Lígia A. Gonçalves A1 Nádia Duarte A1 Patrícia C. Borges A1 Christian Diwo A1 Rute Castro A1 Paula Matoso A1 Vanessa Malheiro A1 Ana Brennand A1 Lindsay Kosack A1 Onome Akpogheneta A1 João M. Figueira A1 Conceição Cardoso A1 Ana M. Casaca A1 Paula M. Alves A1 Carlos Penha-Gonçalves A1 Jocelyne Demengeot YR 2021 UL http://medrxiv.org/content/early/2021/03/24/2021.03.19.21253680.abstract AB While mRNA vaccines authorized for emergency use are administrated worldwide in an effort to contain the COVID19 crisis, little is known about the heterogeneity of the immune response they induce. Here, we report the first 6 weeks of a longitudinal study that quantifies the humoral immune response to BNT162b2 mRNA COVID-19 (Pfizer/BioNTech, Comirnaty) in 1245 health care providers, the Lx1000HCW-PZF cohort. We reveal a striking inter-individual variation 3 weeks after the 1st dose administration that only in part related to age and sex. While population homogeneity in robust IgG responses was reached upon 2nd dose administration, IgM and IgA levels remain low and heterogenous. Our findings of isotypic and heterogenous antibody responses to Comirnaty highlight the need for evaluating the efficacy of COVID-19 mRNA vaccine in preventing infection aside disease, and - contrary to what has been proposed – advocate for the interval between the two doses not to be extended.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work benefited from COVID19 emergency funds 2020 from Fundacao Gulbenkian de Ciencia and from Camara Municipal de Oeiras.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:the Ethics committee of the Centro Hospitalar Lisboa Ocidental in compliance with the Declaration of HelsinkiAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAnonymised raw data for Ig levels will be made available on demand. Biometric data will not be shared.